Anadrol and Superdrol are not interchangeable names. Anadrol is a brand identity for oxymetholone, a prescription anabolic androgenic steroid described in the DailyMed archive as an oral drug for certain anemias caused by deficient red cell production. Superdrol commonly refers to methasterone, also discussed as methyldrostanolone in liver injury literature, a designer anabolic steroid identity rather than a standard prescribed anemia medicine. The useful comparison is identity, label status, liver risk evidence, sport status and warning signs, not which one is safer for a cycle.
This comparison reviews compound identity and risk signals. It does not provide dosing, stack design, product sourcing, injection instructions, after cycle plans, lab targets, legal workarounds or drug testing advice.
Sources checked 2026-09-08. this explanation is educational and cannot decide your diagnosis, prescription status, jurisdiction, sport rules or personal medical risk.
What is the fast answer?
Anadrol points to oxymetholone. Superdrol points most often to methasterone, with methyldrostanolone wording also used in medical literature. Both sit inside anabolic androgenic steroid risk territory, but their evidence trails are different. Anadrol has an archived prescription label. Superdrol appears more often in designer steroid and supplement associated harm reports.
The comparison should start with verified names. Brand names, gym names and seller names can blur identity. Oxymetholone, methasterone and methyldrostanolone are the relevant names to check in medical, law and sport sources. A seller label, capsule color or forum shorthand is not proof of contents.
The safest answer is not a winner. It is a warning about false precision. AAS exposure can affect liver function, blood lipids, blood pressure, fertility, mood, skin, sleep, clot risk and natural hormone signaling. The exact risk depends on the compound, product quality, route, other substances, duration and the person taking it.
Which identities need to be checked first?
| Search name | Most useful compound name | What that means |
|---|---|---|
| Anadrol | Oxymetholone | An archived DailyMed label describes Anadrol-50 tablets as oxymetholone, an oral Schedule III anabolic androgenic steroid. |
| Superdrol | Methasterone | The WADA list names methasterone under anabolic androgenic steroids, and PubMed indexes Superdrol methasteron liver injury literature. |
| Methyldrostanolone | Related Superdrol wording | AAS liver injury reviews use methyldrostanolone wording in cases connected with designer steroid products. |
| Oxandrolone | Different compound | Oxandrolone is not Anadrol and is not Superdrol. It should not be used to define either named product. |
| Retail product name | Unverified label claim | A bottle or online listing may not prove the active substance, strength, contaminants or legal status. |
This identity check counts because many pages compare reputation rather than substance. If the names are wrong, every later claim about effect, risk, legality and monitoring becomes weaker.
How do they compare across matched points?
| Attribute | Anadrol | Superdrol |
|---|---|---|
| Core identity | Oxymetholone. | Methasterone or methyldrostanolone wording in designer steroid contexts. |
| Typical route in records | Oral prescription tablet in the archived label. | Often discussed as an oral bodybuilding or designer steroid product. |
| Medical label context | Label describes use for certain anemias and warns it should not replace supportive measures. | Not treated here as a standard approved prescription anemia medicine. |
| Liver concern | Label warns about peliosis hepatitis, liver tumors, cholestatic hepatitis and jaundice with 17 alpha alkylated androgens. | PubMed literature includes Superdrol methasteron cholestasis and renal failure case reporting. |
| Lipid and heart context | Label describes HDL decrease and sometimes LDL increase with atherosclerosis and coronary risk concern. | FDA bodybuilding product warnings list serious reactions linked to steroid like substances, including heart attack, stroke and clots. |
| Sport status | WADA lists oxymetholone under anabolic androgenic steroids. | WADA lists methasterone under anabolic androgenic steroids. |
| Practical limit | A prescription label does not check bodybuilding misuse. | A supplement or designer label does not prove safety, legality or contents. |
Which liver risks and warning signs count?
Liver risk is central for this comparison because both identities are associated with oral AAS or designer steroid language. DailyMed’s Anadrol label warns about peliosis hepatitis, liver cell tumors, cholestatic hepatitis and jaundice, and it recommends periodic liver function tests in prescribed medical use. LiverTox describes cholestasis after C17 alpha alkylated androgenic steroid exposure and lists oxymetholone as Anadrol.
For Superdrol, PubMed indexes a case report and review titled around severe cholestasis and renal failure linked with Superdrol methasteron. A later PubMed indexed AAS liver injury review reported methyldrostanolone as the most common AAS in its reviewed cases and described common presentation with jaundice and itching.
Those sources are not a formula for ranking harm. They show that both identities belong in a high caution liver risk conversation. Jaundice, dark urine, severe itching, abdominal pain, nausea with weakness, fever, confusion or feeling very unwell after use should move the question from comparison to medical care.
| Signal | Why it counts | Safer response |
|---|---|---|
| Yellow skin or eyes | May indicate jaundice or bile flow problems. | Seek medical assessment promptly, especially with dark urine or severe itching. |
| Right upper abdominal pain | Can occur with liver or bile duct problems and can be mistaken for other illness. | Do not treat it as a normal training issue. |
| Dark urine or pale stools | Can fit a cholestatic pattern when paired with other symptoms. | Tell a clinician exactly what product was used. |
| Severe itching with fatigue | AAS liver injury reports often describe itching and jaundice. | Get checked rather than adding liver support products. |
| Confusion, bleeding or collapse | Could signal severe illness. | Use emergency care. |
What medical status, law and sport rules count?
Anadrol has a prescription drug label history. That does not turn nonmedical oxymetholone use into medical treatment. The DailyMed archive says Anadrol-50 is Schedule III and states that anabolic steroids have not been shown to improve athletic ability. A label for a narrow medical use cannot be stretched into a physique protocol.
Superdrol’s risk profile is harder for consumers because it is often encountered through designer steroid or supplement style marketing. FDA warns that some bodybuilding products may illegally contain steroids or steroid like substances, may be labeled as dietary supplements despite not meeting those requirements, and may carry serious liver, heart, mood, sexual and clot related risks.
Sport status is its own check. The WADA 2026 Prohibited List places anabolic agents in S1, prohibited at all times, and names both methasterone and oxymetholone under anabolic androgenic steroids. Retail access, forum status, prescription history and sport status are different systems.
| Status check | Anadrol issue | Superdrol issue |
|---|---|---|
| Medical approval | Specific oxymetholone label context for anemias. | designer steroid identity, not a self care medicine. |
| Prescription control | Schedule III label history in the United States archive. | Retail claims do not prove lawful supply. |
| Sport rules | Oxymetholone is named in WADA anabolic agents. | Methasterone is named in WADA anabolic agents. |
| Product verification | Pharmacy supply is not the same as underground sale. | supplement style marketing is not proof of contents. |
| Personal safety | Requires clinician context, contraindication checks and monitoring. | Requires clinician context when exposure or symptoms occur. |
What does marketing get wrong?
Marketing often turns this comparison into a strength contest: harsher, drier, wetter, stronger, cleaner, faster, better for a look. Those words are not clinical evidence. They flatten identity, route, product quality, health history and symptom risk into a simple gym narrative.
A second problem is borrowed legitimacy. Anadrol’s prescription label history can be misused to make unsupervised use sound medical. Superdrol’s supplement style history can be misused to make a designer steroid sound less serious. Both moves are weak. Medical labels and retail labels answer different questions, and neither creates a safe personal plan.
| Claim | Why it is weak | Better question |
|---|---|---|
| Anadrol is safer because it was a medicine | A prescription label does not check nonmedical use. | What diagnosis, product, clinician and monitoring exist? |
| Superdrol is safer because it was sold like a supplement | supplement style marketing does not prove contents or safety. | What is the exact compound and source quality? |
| One is clearly stronger | Strength claims often come from anecdotes and mixed products. | What evidence is being compared on matched outcomes? |
| Liver support solves the issue | A support product cannot cancel AAS liver risk signals. | What symptoms or labs require medical care? |
| Normal labs prove safety | One test snapshot cannot rule out future harm or hidden contents. | What risks remain despite the test? |
How can you use the comparison safely?
Use the comparison to correct identity before you act on any claim. If someone says Anadrol, translate that to oxymetholone and read the label warnings in context. If someone says Superdrol, translate that to methasterone or methyldrostanolone language and check designer steroid harm literature plus sport rules. If the product name is vague, the uncertainty is part of the risk.
Do not treat a comparison page as a way to choose between harms. The safer task is to map what is known, what is unknown and what needs care. Known: both names connect to anabolic androgenic steroid risk. Unknown: the real contents of many nonmedical products, the dose, contaminants, other substances, and personal risk factors. Care: symptoms, fertility goals, mental health, liver concerns, cardiovascular risk and stopping problems deserve clinician input.
| person question | Useful answer | What not to infer |
|---|---|---|
| Are they the same thing? | No. Anadrol is oxymetholone; Superdrol commonly points to methasterone. | Do not merge brand names into one risk profile. |
| Does Anadrol’s label make misuse safer? | No. A medical label is tied to an indication and supervision. | Do not borrow medical legitimacy for physique use. |
| Does Superdrol’s retail history make it milder? | No. designer steroid products can still carry serious harm. | Do not treat supplement style marketing as evidence. |
| Can liver risk be ranked cleanly? | Not from search claims. Both have strong caution signals. | Do not use a ranking to ignore symptoms. |
| Can an athlete rely on store availability? | No. WADA names both relevant compounds under prohibited anabolic agents. | Do not confuse retail status with sport permission. |
What should you ask a clinician?
If you have used either product or think you may have taken a mislabeled product, a clinician can still help when the exact contents are unclear. Bring the claimed name, product photos, dates used, route, other substances, alcohol use, symptoms, prior labs and any history of blood pressure, liver, kidney, clotting, fertility or mental health concerns.
FDA advises people using bodybuilding products that claim to contain steroids or steroid like substances to consult a health care professional because of serious health risks and possible withdrawal problems from stopping quickly. That advice is especially relevant when a product was bought online, recommended by a seller, promoted as liver safe, or stacked with other products.
| Bring this | Why it helps |
|---|---|
| Product photos and claimed name | They give a starting point even when contents are unverified. |
| Dates and route | Timing helps link symptoms with exposure and testing needs. |
| Other substances | Stacks can change liver, mood, clot, heart and hormone effects. |
| Symptoms and important signs | Chest, neurologic, liver and psychiatric symptoms may need urgent action. |
| Fertility goals | External androgen exposure can affect reproductive planning. |
What is the plain language answer?
Anadrol vs Superdrol is not a choice between a clean option and a dirty option. It is a comparison between oxymetholone, a labeled anabolic androgenic steroid with serious warnings, and Superdrol associated methasterone or methyldrostanolone language, a designer steroid identity with published liver injury signals. Both deserve a high caution, not prescriptive frame.
The best use of this explanation is to name the compound, check the evidence category, recognize liver and cardiovascular warning signs, and move health questions to a qualified professional. A page that ranks products would create false certainty. A page that clarifies identity and risk can help people step away from that false certainty.
What should you read next?
Which sources support this explanation?
- DailyMed archive: Anadrol-50 oxymetholone label. Used for Anadrol identity, oral route, labeled medical context, Schedule III status and warnings.
- NCBI LiverTox: Androgenic Steroids. Used for AAS liver injury pattern and oxymetholone trade name context.
- PubMed: Severe cholestasis and renal failure associated with Superdrol methasteron. Used for Superdrol associated liver and renal harm signal.
- PubMed: AAS drug induced liver injury review. Used for methyldrostanolone and AAS DILI context.
- WADA 2026 Prohibited List. Used for sport status of oxymetholone and methasterone.
- FDA: Caution: Bodybuilding Products Can Be Risky. Used for bodybuilding product, hidden steroid like ingredient and warning sign context.
- Endocrine Society: Adverse Health Consequences of performance enhancing Drugs. Used for class level PED/AAS health risk context.
- MedlinePlus: Anabolic Steroids. Used for plain language AAS definition, routes, misuse risks and withdrawal context.